Skip to main content

Table 1 Expression of coinhibitory receptors and their ligands in immune cell populations

From: Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Coinhibitory receptor Expression in human CTLs Expression in human NK cells Expression in other immune cell populations Ligand-expressing cells
2B4 (CD244, SLAMF4) Subsets of CTLs and increased in tumor-infiltrating CTLs Subsets of NK cells DCs, monocytes, MDSCs and basophils CD48 (SLAMF2): Lymphocytes, DCs, monocytes, macrophages, endothelial cells and tumor cells
BTLA Subsets of CTLs and increased in tumor-infiltrating CTLs Not expressed B cells and DCs HVEM: T cells, B cells, NK cells, DCs, monocytes and tumor cells
CD200R Subsets of CTLs Subsets of NK cells Th cells, B cells, DCs, macrophages and neutrophils CD200: T cells, B cells, DCs, endothelial cells and tumor cells
CD47 (IAP) Subsets of CTLs Subsets of NK cells Expressed ubiquitously in human cells SIRPα: DCs, macrophages, monocytes and granulocytes
TSP1: Endothelial cells, monocytes, macrophages, granulocytes and cancer cells
CD96 (TACTILE) Subsets of CTLs and increased in tumor-infiltrating CTLs Subsets of NK cells and increased in tumor-infiltrating NK cells Treg cells PVR (CD155. Necl-5): DCs, neutrophils, macrophages and tumor cells
Nectin-1 (PVRL1, CD111): DCs and tumor cells
CTLA-4 Subsets of CTLs and increased in tumor-infiltrating CTLs Unclear Th cells and Treg cells CD80 (B7–1): B cells, T cells, DCs, macrophages and tumor cells
CD86 (B7–2): B cells, T cells, DCs, macrophages and tumor cells
ILT2 (LIR1) Subsets of CTLs and increased in tumor-infiltrating CTLs Subsets of NK cells and increased in tumor-infiltrating NK cells Th cells, B cells, DCs and MDSCs HLA-G: Tumor cells
HLA-I (A/B/C): Ubiquitously in human cells
KIR-L Subsets of CTLs and increased in tumor-infiltrating CTLs Subsets of NK cells and increased in tumor-infiltrating NK cells Th cells HLA-I (A/B/C): Ubiquitously in human cells
KLRG1 Subsets of CTLs and increased in tumor-infiltrating CTLs Subsets of NK cells Not expressed E-cadherin: Epithelial cells and cancer cells
N-cadherin: Mesenchymal cells and cancer cells
R-cadherin: Neural tissue
LAG-3 Subsets of CTLs and increased in tumor-infiltrating CTLs Subsets of NK cells Th cells, Treg cells, B cells and DCs HLA-II: DCs, macrophages, B cells, neutrophils, fibroblasts and tumor cells
FGL-1: Tumor cells
Gal-3: Fibroblasts
LSECtin: Tumor cells
NKG2A/CD94 Subsets of CTLs and increased in tumor-infiltrating CTLs Subsets of NK cells and increased in tumor-infiltrating NK cells Not expressed HLA-E: Ubiquitously in human cells and increased in tumor cells
PD-1 Subsets of CTLs and increased in tumor-infiltrating CTLs Expressed in tumor-infiltrating NK cells Th cells, Treg cells, B cells, macrophages and DCs PD-L1 (B7-H1): Treg cells, B cells, DCs, macrophages, monocytes, MDSCs and tumor cells.
PD-L2 (B7-DC): DCs, macrophages, B cells and tumor cells.
PVRIG (CD112R) Subsets of CTLs and induced in tumor-infiltrating CTLs Subsets of NK cells and increased in tumor-infiltrating NK cells Not expressed Nectin-2 (PVRL2, CD112): DCs, endothelial cells, and tumor cells
Siglec-7/−9 Siglec-7: Subsets of CTLs,
Siglec-9: Subsets of CTLs and induced in tumor-infiltrating CTLs
Siglec-7: Subsets of NK cells,
Siglec-9: Subsets of NK cells
Siglec-7: Macrophages, monocytes and mast cells
Siglec-9: DCs, macrophages, monocytes and neutrophils
Sialic acid-containing ligands: Glycoproteins expressed by human cells. Hypersialylation, xenosialylation, and sialic acid alterations in tumor cells
TIGIT Subsets of CTLs and increased in tumor-infiltrating CTLs Subsets of NK cells and increased in tumor-infiltrating NK cells Th cells and Treg cells PVR (CD155, Necl-5): DCs, neutrophils, macrophages and tumor cells
Nectin-2 (PVRL2, CD112): DCs, endothelial cells, and tumor cells
Nectin-3 (PVRL3, CD113): DCs, endothelial cells, T cells and tumor cells
TIM-3 Subsets of CTLs and increased in tumor-infiltrating CTLs Subsets of NK cells and increased in tumor-infiltrating NK cells Th cells, Treg cells, DCs, macrophages and monocytes Galectin-9: T cells, Treg cells, NK cells, B cells, macrophages, endothelial cells and mast cells and tumor cells.
PS: Inner-cell membrane phospholipid of human cells.
HMGB1: NK cells, DCs, macrophages and tumor cells
CEACAM1: T cells, B cells, NK cells, neutrophils, monocytes and tumor cells
Undiscovered B7-H3 receptor / / / B7-H3: T cells, B cells, NK cells, monocytes and tumor cells
VISTA (PD-1H) Subsets of CTLs and increased in tumor-infiltrating CTLs Not expressed Th cells, Treg cells, DCs, macrophages, monocytes, neutrophils and basophils PSGL-1: T cells, B cells, DCs, macrophages, monocytes, endothelial cells, and neutrophils
  1. CTLs cytotoxic T lymphocytes, NK natural killer, DCs dendritic cells, MDSCs myeloid-derived suppressor cells, BTLA B and T cell lymphocyte attenuator, HVEM herpesvirus entry mediator, Th T-helper, SIRPα signal regulatory protein alpha, TSP1 thrombospondin-1, Treg T-regulatory, ILT2 immunoglobulin-like transcript-2, KIR-L killer immunoglobulin-like receptor long cytoplasmic tail, LAG3 lymphocyte activation gene-3, FGL-1 fibrinogen-like protein 1, Gal-3 galectin-3, NKG2A natural killer group 2A, PD-1 programmed cell death protein 1, PD-L1 programmed death-ligand 1, PD-L2 programmed cell death 1 ligand 2, TIGIT T cell immunoglobulin and ITIM domain, TIM-3 T-cell immunoglobulin and mucin-domain containing-3, PS phosphatidylserine (PS), HMGB1 high-mobility group protein 1, CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1, VISTA V-domain Ig suppressor of T cell activation, PSGL-1 P-selectin glycoprotein ligand 1